Company Focus
Sanofi
Latest Sanofi News
Pharmaceutical
Merck & Co was the biggest spender in pharma M&A during July. 7 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Sanofi
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Pharmaceutical
Evotec reported second-quarter 2025 revenues of $188 million, down 6% year-on-year, as strength in its biologics division partly offset weaker demand in discovery and preclinical services. Net loss narrowed to $48 million from $103 million, with earnings per share at minus $0.24. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 clinical trial (also known as KEYNOTE-905). 12 August 2025
Generics
US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients aged two years of age and older, with chronic kidney disease (CKD). 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 12 August 2025
Biotechnology
Castleman’s disease (CD) refers to a group of rare lymphoproliferative disorders characterized by abnormal lymph node architecture and systemic inflammation. 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Biotechnology
Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio (imsapepimut and etimupepimut 11 August 2025
Latest In Brief for Sanofi
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze